Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 12:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,140 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Flu Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Pomegranate Products for Prevention of Common Cold

NCT00617318
View directory record Official record
Conditions
Influenza, Common Cold, Cough, Headache, Fever
Interventions
Pomegranate, Placebo
Dietary Supplement
Lead sponsor
Texas Heart Institute
Other
Eligibility
21 Years to 49 Years
Enrollment
461 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2008 · Synced Oct 21, 2026, 12:39 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children

NCT00192322
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T 10^7, CAIVT 10^5, Placebo, TIV
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 36 Months
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
2
States / cities
New Port Richey, Florida • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 21, 2026, 12:39 PM EDT
Completed Phase 4 Interventional Results available

ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir

NCT02609399
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Peramivir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 21, 2026, 12:39 PM EDT
Completed Phase 1 Interventional

Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers

NCT02594189
View directory record Official record
Conditions
Determine Minimally to Moderately Infective Dose (MMID) of Influenza A H3N2
Interventions
Live recombinantly derived A/Bethesda/MM1/H3N2 virus
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 21, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults

NCT01059617
View directory record Official record
Conditions
Influenza
Interventions
GSK Biologicals' FluLaval®, Placebo (saline), GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 40 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Milford, Massachusetts • Salisbury, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 21, 2026, 12:39 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Influenza Immunity Against Pandemic Respiratory Virus

NCT00138281
View directory record Official record
Conditions
Influenza
Interventions
FluMist, Fluzone
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 21, 2026, 12:39 PM EDT
Recruiting No phase listed Observational

Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India

NCT06168019
View directory record Official record
Conditions
Influenza, COVID-19, SARS-COV-2 Infection, Other Respiratory Viruses, Perinatal Morbidity, Infant Morbidity
Interventions
Exposures
Other
Lead sponsor
Boston University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
10,000 participants
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 21, 2026, 12:39 PM EDT
Not listed Not applicable Interventional

Immunogenicity of Influenza Vaccine in Long Term Care

NCT02933723
View directory record Official record
Conditions
Influenza
Interventions
Blood Draw
Procedure
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 21, 2026, 12:39 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma

NCT00978120
View directory record Official record
Conditions
H1N1 Influenza Virus
Interventions
H1N1 vaccine high dose, H1N1 vaccine low dose
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Atlanta, Georgia • St Louis, Missouri • Winston-Salem, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2012 · Synced Oct 21, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults

NCT03814720
View directory record Official record
Conditions
Influenza Infection
Interventions
VRC-FLUNPF099-00-VP (H1ssF_3928)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 21, 2026, 12:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

NCT00964821
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 21, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N1 Mix and Match With AS03

NCT01317758
View directory record Official record
Conditions
Influenza
Interventions
AS03 Adjuvant, Phosphate Buffered Saline (PBS) diluent, Sanofi H5N1 Antigen
Drug · Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
4
States / cities
Baltimore, Maryland • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 21, 2026, 12:39 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

NCT05827978
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8,411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
103
States / cities
Anniston, Alabama • Athens, Alabama • Cullman, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 21, 2026, 12:39 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

NCT06864143
View directory record Official record
Conditions
Influenza, SARS-CoV-2
Interventions
mRNA-1083 Composition 1 Dose A Lot A, mRNA-1083 Composition 1 Dose A Lot B, mRNA-1083 Composition 1 Dose B, mRNA-1083 Composition 1 Dose C, mRNA-1083 Composition 2 Dose A, mRNA-1083 Composition 2 Dose B, mRNA-1083 Composition 3 Dose A, mRNA-1083 Composition 3 Dose B, Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza Vaccine, Investigational COVID-19 Vaccine Lot A, Investigational COVID-19 Vaccine Lot B
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
17
States / cities
Scottsdale, Arizona • San Diego, California • Stockbridge, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 21, 2026, 12:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza

NCT00391768
View directory record Official record
Conditions
Influenza
Interventions
oseltamivir (Tamiflu®)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 23 Months
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
29
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 21, 2026, 12:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ACTIVATE in Public Housing

NCT06075732
View directory record Official record
Conditions
Pneumonia, Influenza, Varicella Zoster, Meningitis, COVID-19, Vaccine Hesitancy
Interventions
Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination
Behavioral
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 21, 2026, 12:39 PM EDT
Completed Not applicable Interventional Results available

Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza

NCT00555893
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
1 Year to 79 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 21, 2026, 12:39 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

NCT03376321
View directory record Official record
Conditions
Influenza A
Interventions
Pimodivir 600 mg, Placebo, SOC Treatment
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
13 Years to 85 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 21, 2026, 12:39 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

NCT05624606
View directory record Official record
Conditions
Influenza Immunization
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5410, Quadrivalent Recombinant Influenza vaccine RIV4, Quadrivalent Inactivated Influenza Standard Dose QIV-SD, Quadrivalent Inactivated Influenza High Dose QIV-HD
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
23
States / cities
Huntington Park, California • Long Beach, California • North Hollywood, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 21, 2026, 12:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age

NCT01985997
View directory record Official record
Conditions
Observation Safety
Interventions
Not listed
Lead sponsor
MedImmune LLC
Industry
Eligibility
Not listed
Enrollment
95,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Oct 21, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally

NCT00436046
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza virus vaccine (2006-2007 formulation), Type 1 interferon
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Oct 21, 2026, 12:39 PM EDT
Completed Not applicable Interventional Results available

System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts

NCT02266277
View directory record Official record
Conditions
Influenza, Infections, Pneumococcal
Interventions
Arm 1: E-portal message with IVR call, Arm 2: E-portal message with no IVR call, Arm 3: No e-portal message with IVR call, Arm 5: IVR call
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 21, 2026, 12:39 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks

NCT05012189
View directory record Official record
Conditions
Influenza, Influenza, Human, Influenza -Like Illness
Interventions
Oseltamivir, Baloxavir
Drug
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
18 Years to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 21, 2026, 12:39 PM EDT
Completed Not applicable Interventional

Pediatric Second Influenza Dose Portal Reminder Recall

NCT04668417
View directory record Official record
Conditions
Influenza, Respiratory Tract Infections
Interventions
Portal Reminders for Second Dose of Influenza Vaccine with Direct Scheduling Link, Portal Reminders for Second Dose of Influenza Vaccine without Direct Scheduling Link
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Months to 36 Months
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 21, 2026, 12:39 PM EDT